Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W. Noble, Roland M. du Bois, Dominique Valeyre et al.|The Lancet|2011Cited by 2.1k
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W. Noble, Talmadge E. King, Carlo Albera et al.|European Respiratory Journal|2015Cited by 462
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisSteven D. Nathan, Paul W. Noble, Carlo Albera et al.|The Lancet Respiratory Medicine|2016Cited by 331
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 studyJoshua J. Solomon, Marilyn K. Glassberg, Sonye K. Danoff et al.|The Lancet Respiratory Medicine|2022Cited by 211
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision MedicineAyodeji Adegunsoye, David A. Schwartz, Jonathan A. Kropski et al.|American Journal of Respiratory and Critical Care Medicine|2024Cited by 58